Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.46 |
| ▸ | GHSR | Q92847 | 3/20 | 0.46 |
| ▸ | CTSV | O60911 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 9/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1461108 | 0.88 | GHSR (0.47) | GHSRCTSVCTSLHTR2AGPR84 | |
| SCHEMBL865468 | 0.81 | HTR1A (0.43) | LOXL2GHSRCTSVCTSLHTR2A | |
| SCHEMBL3698687 | 0.79 | LOXL2 (0.57) | LOXL2GHSRCTSVCTSLGPR84 | |
| SCHEMBL28285787 | 0.79 | GHSR (0.48) | GHSRCTSVCTSLGPR84 | |
| SCHEMBL3701458 | 0.79 | LOXL2 (0.57) | LOXL2GHSRCTSVCTSLGPR84 | |
| SCHEMBL1459106 | 0.77 | GHSR (0.46) | LOXL2GHSRCTSVCTSLGPR84 | |
| SCHEMBL9278047 | 0.77 | GPR84 (0.50) | GHSRCTSVCTSLGPR84 | |
| SCHEMBL864947 | 0.76 | KDM4E (0.43) | LOXL2GPR84HTR1AHTR1DHTR1B | |
| SCHEMBL3702698 | 0.76 | CTSV (0.63) | LOXL2GHSRCTSVCTSLGPR84 | |
| SCHEMBL11415263 | 0.76 | CTSV (0.63) | LOXL2GHSRCTSVCTSLGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION | 2011-11-10 | — | — | US | disclosed |
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION | 2011-11-10 | — | — | US | disclosed |
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION | 2011-11-10 | — | — | US | disclosed |
| WO-2010033701-A2 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | SPHK1, SPHK2, S1PR1 | LOXL2 1440/4885GHSR 2006/4885CTSV 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.